Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an EULAR task force

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 952-957

  Strehl, Cindy ^a   Bijlsma, Johannes W J ^b,c   De Wit, Maarten ^c   Boers, Maarten ^c   Caeyers, Nele ^d   Cutolo, Maurizio ^e   Dasgupta, Bhaskar ^f   Dixon, William G ^g   Geenen, Rinie ^h   Huizinga, Tom W J ⁱ   Kent, Alison ^j   De Thurah, Annette Ladefoged ^k   Listing, Joachim ^l   Mariette, Xavier ^m,n   Ray, David W ^g   Scherer, Hans U ⁱ   Seror, Raphaèle ^m,n   Spies, Cornelia M ^a   Tarp, Simon ^o   Wiek, Dieter ^p   Winthrop, Kevin L ^q   Buttgereit, Frank ^a   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Patient Research Partner   (Belgium)

^e UNIVERSITY OF GENOA   (Italy)

^f SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UTRECHT UNIVERSITY   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l German Rheumatism Research Centre   (Germany)

^m BICÊTRE HOSPITAL   (France)

ⁿ UNIVERSITÉ PARIS SACLAY   (France)

^o Mental Health Center Glostrup   (Denmark)

^p Deutsche Rheuma Liga   (Germany)

^q OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIET; DOSE RESPONSE; EXERCISE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; INFECTION; INFECTION RISK; LONG TERM CARE; LOW DRUG DOSE; OBESITY; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTECTION; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; SODIUM RESTRICTION; STRUCTURED QUESTIONNAIRE; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT REDUCTION; ADVISORY COMMITTEE; CONSENSUS; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PROCEDURES; RHEUMATIC DISEASES; TIME FACTOR;

ADVISORY COMMITTEES; CONSENSUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLUCOCORTICOIDS; HUMANS; LONG-TERM CARE; RHEUMATIC DISEASES; RISK FACTORS; TIME FACTORS;

EID: 84960917952     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208916     Document Type: Review

References (79)

1. Duru N, Van Der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905-13.
2. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7.
3. Van Der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69:1913-19.
4. Gaujoux-Viala C, Gossec L. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. Ann N Y Acad Sci 2014;1318:32-40.
5. Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-14.
6. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015;74:1799-807.
7. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
8. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360-70.
9. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329-39.
10. Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012;14: R112.
11. Neovius M, Simard JF, Askling J, et al. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011;70:624-9.
12. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009;68:1119-24.
13. Ethgen O, De Lemos Esteves F, Bruyere O, et al. What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin 2013;29:1147-60.
14. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013;173:743-52.
15. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
16. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-7.
17. Saag KG, Criswell LA, Sems KM, et al. Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996;39:1818-25.
18. Thiele K, Buttgereit F, Huscher D, et al. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Care Res 2005;53:740-7.
19. Bazsó A, Szappanos Á, Patócs A, et al. The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic review. Autoimmun Rev 2015;14:349-51.
20. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
21. Van Der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69:1015-21.
22. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 2015;11:98-109.
23. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
24. Briot K, Cortet B, Roux C, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 2014;81:493-501.
25. Wikstrom AC. Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness. J Endocrinol 2003;178:331-7.
26. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
27. Goemaere S, Liberman UA, Adachi JD, et al. Incidence of nonvertebral fractures in relation to time on treatment and bone density in glucocorticoid-treated patients: a retrospective approach. J Clin Rheumatol 2003;9:170-5.
28. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785-91.
29. Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011;38:1601-6.
30. Rostom S, Mengat M, Lahlou R, et al. Metabolic syndrome in rheumatoid arthritis: case control study. BMC Musculoskelet Disord 2013;14:147.
31. Tatsuno I, Sugiyama T, Suzuki S, et al. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 2009;94:1671-7.
32. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9.
33. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-9.
34. Johansson H, Kanis JA, Odén A, et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 2014;29:223-33.
35. Villa P, Moruzzi MC, Lassandro AP, et al. Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population. Gynecol Endocrinol 2013;29:678-82.
36. Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 2012;52:580-93.
37. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012;41:595-611.
38. Mitra R. Adverse effects of corticosteroids on bone metabolism: a review. PM R 2011;3:466-71; quiz 471.
39. Van Der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int 2013;24:1429-36.
40. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 2011;63:325-8.
41. Compston J. Clinical question: What is the best approach to managing glucocorticoid-induced osteoporosis? Clin Endocrinol (Oxf) 2011;74:547-50.
42. Mok CC, Ying KY, To CH, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 2011;70:778-84.
43. Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4.
44. Crowson CS, Hoganson DD, Fitz-Gibbon PD, et al. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2847-55.
45. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128-33.
46. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011;13:R139.
47. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53-61.
48. Curtis JR, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012;64:1480-9.
49. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
50. Matsumoto Y, Sada KE, Takano M, et al. Risk factors for infection in patients with remitted rheumatic diseases treated with glucocorticoids. Acta Med Okayama 2011;65:329-34.
51. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
52. Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin North Am 2012;38: 727-45.
53. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014;73:1673-6.
54. Raul Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, et al. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998;29:259-62.
55. Su CC, Chen IeC, Young FN, et al. Risk of diabetes in patients with rheumatoid arthritis: a 12-year retrospective cohort study. J Rheumatol 2013;40:1513-18.
56. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis 2011;70:1881-3.
57. Den Uyl D, Van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012;64:639-46.
58. Bili A, Sartorius JA, Kirchner HL, et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011;17:115-20.
59. Ito S, Ogishima H, Kondo Y, et al. Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases. Mod Rheumatol 2014;24:52-9.
60. Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 2011;104:13-26.
61. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65.
62. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:450-62.
63. Solomon DH, Curhan GC, Rimm EB, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004;50:3444-9.
64. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7:399-408.
65. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ 2012;345: e4928.
66. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
67. Strohmayer EA, Krakoff LR. Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am 2011;40:409-17, x.
68. Del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Ann Rheum Dis 2014;66:264-72.
69. Ajeganova S, Andersson ML, Frostegard J, et al. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 2013;40:1958-66.
70. Soubrier M, Barber Chamoux N, Tatar Z, et al. Cardiovascular risk in rheumatoid arthritis. Joint Bone Spine 2014;81:298-302.
71. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21.
72. Cambridge G, Acharya J, Cooper JA, et al. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013;228:243-6.
73. Davis JM III, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;56:820-30.
74. Turesson C, McClelland RL, Christianson TJ, et al. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:70-5.
75. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA 2002;288:2569-78.
76. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen Van Zanten JJ, et al. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis 2014;73:748-51.
77. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
78. Negri E, La Vecchia C, D'Avanzo B, et al. Acute myocardial infarction: association with time since stopping smoking in Italy. GISSI-EFRIM Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto. Epidemiologia dei Fattori di Rischio dell'Infarto Miocardico. J Epidemiol Community Health 1994;48:129-33.
79. Buttgereit F, Burmester GR, Lipworth BJ. Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol 2009;5:18-9.